LBA17 Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB)

G. N. Hortobágyi, Salomon M. Stemmer, H.A. Burris, Yoon Sim Yap, Gabe S. Sonke, L. Hart, M. Campone, Katarína Petráková, Eric P. Winer, W Janni, PierFranco Conte, David Cameron, Fabrice André, CL Arteaga, Juan Pablo Zarate, A. Chakravartty, Tanya Taran, Fabienne Le Gac, Patrizia Serra, Joyce O’Shaughnessy